Skip to main content
BioSenic SA logo

BioSenic SA — Investor Relations & Filings

Ticker · BIOS ISIN · BE0974280126 LEI · 549300HFIIMTOP1DFR76 BR Professional, scientific and technical activities
Open in API
Filings indexed 968 across all filing types
Latest filing 2023-06-14 Declaration of Voting R…
Country BE Belgium
Listing BR BIOS

About BioSenic SA

http://www.biosenic.com/

BioSenic SA is a biotechnology company focused on developing innovative treatments for autoimmune diseases, inflammatory conditions, and bone disorders. The company's core activities are centered on two main technology platforms: one based on arsenic trioxide (ATO) for its immunomodulatory properties, and another involving allogeneic cell therapy for tissue repair and regeneration. BioSenic's objective is to address significant unmet medical needs in the fields of regenerative and immune medicine by advancing its clinical assets through development.

Recent filings

Filing Released Lang Actions
BioSenic SA - Procès-verbal AGO - 14062023.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a 'Procès-verbal de l'assemblée générale ordinaire' (Minutes of the Ordinary General Meeting) for BioSenic, dated June 14, 2023. It details the attendance, agenda items, and the specific voting results for each resolution passed during the meeting (e.g., approval of annual accounts, discharge of directors, and confirmation of board appointments). Since the document provides the official record of the voting outcomes and decisions made at the AGM, it is classified as a Declaration of Voting Results.
2023-06-14 French
BIOS_PR_2023-06-01_Denominator_EN_vfinal.pdf
Share Issue/Capital Change Classification · 98% confidence The document is explicitly titled 'PRESS RELEASE – REGULATED INFORMATION' and announces 'Information on the total number of voting rights and shares'. It details the change in the total number of shares and voting rights due to the conversion of convertible bonds, citing compliance with Article 15 of the Belgian Law of 2 May 2007 regarding major shareholdings. This content directly relates to changes in the total number of shares and voting rights, which falls under the category of Share Issue/Capital Change (SHA) or potentially a general Regulatory Filing (RNS). Since the core subject is the calculation and announcement of the total number of shares/voting rights (the denominator), it is most accurately classified as a Share Issue/Capital Change (SHA), as it results from a capital event (bond conversion leading to new shares). It is not a general earnings release (ER), a proxy statement (PSI), or a director's dealing (DIRS).
2023-06-01 English
BIOS_PR_2023-05-01_Denominator_FR_vfinal.pdf
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is titled "COMMUNIQUE DE PRESSE – INFORMATION REGLEMENTEE" and dated 01/06/2023. The core content details an 'Information relative au nombre total de droits de vote et d'actions' (Information relative to the total number of voting rights and shares) following the issuance of new shares due to convertible bond conversion. This announcement explicitly reports changes in the total number of shares and voting rights, referencing the Belgian law on the declaration of significant shareholdings. This type of mandatory disclosure regarding changes in the denominator (total shares/voting rights) is a specific regulatory filing, but among the provided codes, it most closely relates to changes in share capital or major shareholding notifications. Since it is a formal announcement detailing the change in the total number of shares (124,008,857 to 126,508,857), it fits the description of a notification regarding share capital changes or major shareholding changes. Given the context of reporting the total number of shares/voting rights, which is often required when share counts cross thresholds or change significantly, 'Major Shareholding Notification' (MRQ) or 'Share Issue/Capital Change' (SHA) are candidates. However, the document is a formal press release announcing the new total share count, which is a common trigger for regulatory updates. Since the document explicitly details the issuance of 2,500,000 new shares and the resulting total share count, 'Share Issue/Capital Change' (SHA) is the most precise fit for reporting the mechanics of the capital change itself, although it also serves as a notification of the new total voting rights (denominator). Given the focus on the issuance and the resulting total, SHA is selected over MRQ (which usually focuses on ownership thresholds) or RNS (which is a fallback). The document is a full announcement, not just a notice of publication.
2023-06-01 French
BIOS_PR_2023-05-29_Phebra_EN_vfinal.pdf
Regulatory Filings Classification · 100% confidence The document is a press release dated May 29th, 2023, titled "BioSenic provides update regarding current license agreement with Phebra." It details an amendment to a license agreement, discusses ongoing negotiations, and provides updates on clinical trials (Phase III launch deadline change). This type of announcement, which communicates specific business developments, contractual changes, and operational updates outside of routine financial reporting (like 10-K or ER), typically falls under general regulatory announcements or investor relations communications. Since it is not a formal financial report (10-K, IR, ER), a specific transaction (TAR, CAP), or a management change (MANG), it best fits the general regulatory/investor communication category. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a significant, non-standard corporate update press release, although 'LTR' (Legal Proceedings Report) or 'IR' (Interim Report) are clearly incorrect. It is a specific corporate announcement, not a general 'Report Publication Announcement' (RPA) as it contains substantive news, not just a notice that a report is attached. Therefore, RNS is the best fit as a general regulatory/corporate news release.
2023-05-29 English
BIOS_PR_2023-05-29_Phebra_FR_vfinal.pdf
M&A Activity Classification · 99% confidence The document is titled "COMMUNIQUÉ DE PRESSE – INFORMATIN PRIVILEGIEE" (Press Release – Privileged Information) and is dated 29/05/2023. It details an update regarding a license agreement modification between BioSenic and Phebra concerning the OATO formulation, including changes to clinical trial deadlines and potential renegotiations of commercial terms. This type of announcement, which communicates material, non-public information about corporate agreements, strategic updates, and operational milestones (like clinical trial progression), is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a formal press release announcing significant business developments rather than just the release of a full financial report (like 10-K or IR), and it is not a transcript (CT), a proxy statement (PSI), or a director's dealing report (DIRS), the most appropriate classification is Earnings Release (ER) if it contains key financial highlights, or Regulatory Filing (RNS) if it's purely operational/legal news. Given the focus on licensing terms, clinical trial timelines, and strategic updates, it functions as a material corporate announcement. In many contexts, such detailed operational updates released via press release fall under the broader category of Regulatory Filings (RNS) if they don't strictly adhere to quarterly earnings reporting structure, or ER if it's near an earnings period. However, since it is a formal press release announcing a significant business event (license modification), and it is not explicitly an earnings report, RNS is a strong candidate. Reviewing the definitions, ER is for 'Initial announcement of quarterly/periodical financial results (key highlights only)'. This document is about a licensing agreement change, not financial results highlights. Therefore, RNS (General regulatory announcements and fallback category) is the most suitable classification for this specific type of material corporate update that doesn't fit a more specific category like CAP, TAR, or LTR.
2023-05-29 French
BIOS_PR_2023-05-24_Implant_EN_vfinal.pdf
M&A Activity Classification · 99% confidence The document is explicitly titled as a 'PRESS RELEASE – INSIDE INFORMATION' dated May 24th, 2023. It details a significant business development: the signing of a term sheet between BioSenic and Pluristyx regarding a potential license agreement for cell technology (ALLOB). This type of announcement, which communicates material, non-public information about strategic business operations (like potential licensing deals, partnerships, or financing terms) via a press release, typically falls under general regulatory announcements or specific corporate actions. Since it is not a full financial report (10-K, IR), an earnings release (ER), a proxy statement (DEF 14A), or a specific transaction report (like DIRS or POS), the most appropriate classification is the general regulatory announcement category, RNS, as it serves as a broad disclosure mechanism for material news that doesn't fit a narrower category. The length (14,740 chars) confirms it is the full content, not just a brief announcement of a report (which would suggest RPA).
2023-05-24 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.